ArticleFrontiers in oncology2026
Synchronous triple cancers of synchronous endometrial and ovarian carcinoma complicated by renal cancer: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Synchronous primary carcinoma of the endometrium and ovary is rare in clinical practice. Distinguishing between synchronous primary carcinomas and metastatic carcinomas is very important for the selection of subsequent treatment regimens. In addition, triple primary malignancies are even rarer. Here, we report a case of synchronous triple primary malignancies, including primary carcinomas of the endometrium, ovary, and kidney. Case presentation: We report a 60-year-old female patient who was diagnosed as synchronous primary carcinoma of the endometrium and ovary. Comprehensive staging surgery were performed. The molecular subtyping of endometrial cancer was mismatch repair deficiency. The whole-abdomen MRI was performed before the radiotherapy and a mass was found in the right renal parenchyma. The pathology showed papillary renal cell carcinoma. The result of germline genetic testing was negative (also negative for MLH1、MSH2、MSH6、PMS2、EPCAM). No recurrence or metastasis was observed during a 12-month follow-up period. Conclusion: This case report adds to the limited literature on synchronous triple primary malignancies. For synchronous endometrial and ovarian cancer, distinguishing between primary tumors and metastases is clinically critical. Notably, the presence of MMRd subtype in such synchronous tumors does not inherently indicate Lynch syndrome. This case underscores the importance of integrating molecular testing and clinical manifestations to accurately diagnose multiple primary malignancies and formulate tailored treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.